FAS achieved reduction of prices for 207 medicinal drugs

Pharmaceutical companies continue reducing drug prices upon the findings of an international comparative survey carried out by FAS  

Pharmaceutical manufactures reduce prices voluntarily base on the findings of international comparative survey carried out by FAS following the instructions from the President of the Russian Federation. During the two survey stages, the antimonopoly body compared prices for the medicines included in the list of vital and essential drugs, procured by the stated under the “Seven high-cost nosologies programme” as well as for treatment of hepatitis B and C, and for antibacterial and antituberculosis drugs.

Head of FAS Department for Control over Social Sphere and Trade, Timophey Nizhegorodtsev clarified: “As of 6 March 2017, prices reduced for 207 vital and essential drugs, including all prices for the drugs included in the “Seven nosologies” programme. At the moment, 58 prices are decreased at the second stage. The average reduction at the first and second prices was 50% and 36% accordingly. In value terms, the highest reduction at the first stage reached 240,000 RUB for “Revlimid” manufactured by “Celgene”. Pharmaceutical companies voluntarily reduced 24 prices for drugs not covered by the survey”.